Processa Pharmaceuticals (PCSA) Cash from Financing Activities (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Cash from Financing Activities came in at $244783.0 in Q1 2026, down 94.48% YoY from $4.4 million in Q1 2025, and down 91.78% on a QoQ basis from $3.0 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Cash from Financing Activities data on file, last reported at $244783.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 94.48% year-over-year to $244783.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (up 109.79% YoY) and the FY2025 annual result came in at $16.6 million, up 114.4% from the prior year.
- Cash from Financing Activities eased to $244783.0 in Q1 2026, from $3.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $6.4 million in Q1 2023 to a low of -$300000.0 in Q1 2022.
- A 5-year average of $2.0 million and a median of $547582.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 140.8% — and 2025, when it soared 184925.81%.
- Tracing PCSA's Cash from Financing Activities over 5 years: stood at -$53596.0 in 2022, then surged by 42.89% to -$30607.0 in 2023, then soared by 1889.07% to $547582.0 in 2024, then surged by 444.05% to $3.0 million in 2025, then sank by 91.78% to $244783.0 in 2026.
- The last three Cash from Financing Activities figures came in at $244783.0 (Q1 2026), $3.0 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | 315,167.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 244,783.00 |
| Mar 31, 2026 | 244,783.00 |
| Dec 31, 2025 | 2.98 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 2.86 Mn |
| Sep 30, 2025 | 2.86 Mn |
| Jun 30, 2025 | 6.31 Mn |
| Jun 30, 2025 | 6.31 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Dec 31, 2024 | 547,582.00 |
| Dec 31, 2024 | 547,582.00 |
| Sep 30, 2024 | 926,196.00 |
| Sep 30, 2024 | 926,196.00 |
| Jun 30, 2024 | -3,414.00 |
| Jun 30, 2024 | -3,414.00 |
| Mar 31, 2024 | 6.26 Mn |
| Mar 31, 2024 | 6.26 Mn |
| Dec 31, 2023 | -30,607.00 |
| Dec 31, 2023 | -30,607.00 |